Abstract: A combination of t-PA and SOD of use in inhibiting damage to jeopardized tissue during reperfusion in a mammal.

Abstract: This invention relates to a novel method for the delivery of cytotoxic drugs to tumor cells by the administration of a tumor-specific antibody-enzyme conjugate that binds to the tumor cells, and the additional administration of a prodrug that is converted at the tumor site, in the presence of the antibody-bound enzyme, to an active cytotoxic drug. According to preferred embodiments of this invention, antibody-enzyme conjugates containing the enzyme, alkaline phosphatase ("AP"), have been used in conjunction with the novel prodrug, etoposide-4'-phosphate or 7-(2'-aminoethyl phosphate)mitomycin or a combination thereof, to effect killing of tumor cells. According to another embodiment of the invention, an antibody-enzyme conjugate containing the enzyme, penicillin V amidase ("PVA"), has been used in conjunction with a novel prodrug, N-(p-hydroxyphenoxyacetyl)adriamycin to effect killing of tumor cells.

Abstract: The present invention provides salts of organogermanium compounds expressed by the following Formual (a): ##STR1## (wherein M denotes an oxygen or sulfur atom; and R.sub.1, R.sub.2, R.sub.3, and R.sub.4 may be the same or different from each other and each denotes a hydrogen atom, a lower alkyl group, or an aryl group) with compounds having basic groups, and medicines containing the salts such as biological response modifiers and antitumor agents.

Abstract: Wound healing dressings are prepared by flocculating fibronectin, a biologically active fragment or an analog thereof to produce a water-swellable gel. The gels, in the form of sheets, strips, wedges, strands or I-shaped cross-sections, are especially useful in promoting the healing of corneal, scleral dermal, incisional wounds or lesions. They can be used to enhance the results obtained in keratorefractive surgeries and the healing scleral incision for intraocular surgery.

Abstract: Inflammation, acute and/or chronic, is treated with a CIF (TGF-beta). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration of activator or cofactor for efficacy.

Abstract: A novel bath preparation which comprises a whey concentrate of high mineral content and, if necessary, one or more additives commonly used for conventional bath preparations such as inorganic salts, inorganic acid, organic acid, medicinal herbs, fats and oils, dyestuffs, perfumes, alcohols, and polyhydric alcohols.The preparation has the great potential to serve as a curative in the treatment of various disease such as shoulder stiffness, neuralgia, lumbago, rheumatism, etc. It also contributes to beautification.

Abstract: A lyophilised pharmaceutical formulation of tissue plasminogen activator and a process for its preparation by vacuum drying a frozen aqueous solution of thereof, in which the pH is from 2 to 5.

Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.

Abstract: A bilirubin oxidase derivative resulting from chemical modification of a water-soluble polymeric substance. The chemically modified bilirubin oxidase is useful as a drug for treating jaundice.

Abstract: A deer repellent formulation for warding off a deer from a plant is provided. The deer repellent formulation includes, a volume of water; 12 fluid ounces of thiram in a water solution of 42% by volume of thiram, per gallon of the water; 2 whole chicken eggs per gallon of water; 2 ounces by volume of liquid hot sauce per gallon of water; green color dye in a sufficient quantity per gallon of the water to provide a plant-like green color of the formulation; and a liquid adhesive in sufficient quantity per gallon of the water to provide a desired stickiness on plants of the formulation.

Abstract: Highly unsaturated fatty acid compounds, and derivatives thereof, are stabilized against oxidation with a water activated oxidoreductase enzyme. The fatty acid containing component is preferably microencapsulated in a wall member which comprises the enzyme.

Abstract: Growth hormone releasing factor (GRF) preparation which is excellent in stablity by having human serum albumin or glycine incorporated therein, with or without buffer. An amount of human serum albumin or glycine contained is usually 100 .mu.g to 30 mg per 100 .mu.g GRF. The preparation may be in the solid or solution form, preferably in the lyophilized form. An amount of buffer, if added, is preferably enough so that pH of the preparation is kept at 2-7. More preference is that the preparation is kept in nitrogen gas atmosphere. The lyophilized preparation is readily usable for, for example, injection.

Abstract: An aqueous solution comprises lysozyme hydrochloride, dipotassium glycyrrhizinate, at least one selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium phosphate, potassium phosphate, sodium citrate, potassium citrate, sodium carbonate and potassium carbonate and water, has a pH of 5 to 9 and is useful for eye drops.

Abstract: A composition for the treatment of dry skin comprises a mixture of lanolin and lanolin oil. Preferably, the composition contains about 75% by weight of lanolin and about 25% by weight of lanolin oil.

Abstract: A pasteurized human firbinogen which can be used therapeutically, and a process for its preparation are described.

Abstract: A pharmaceutical composition for the treatment and prevention of erythma and acne comprises in a pharmaceutically acceptable carrier from about 1 to 10 weight percent based on the total weight of the composition of a delipidized and purified keratin polymer obtained from animal starting material containing keratin, the keratin polymer being in the free state.

Abstract: A non-toxic, oxidizing-energizing composition suitable for use as an accelerator of the carbohydrate oxidative degradation metabolic process or the direct oxidation of glucose which consists essentially of, by weight, (A) 10% to 95% of flavine-adenine dinucloeotide coenzyme (FAD) and (B) 10% to 95% of at least one coenzyme or enzyme selected from the group consisting of flavine mononucleotide coenzyme (FM), ubiquinone coenzyme (UBQ), uridine 5'-triphosphate coenzyme (UTP), triphosphopyridine nucleotide coenzyme (TPN), diphosphopyridine nucleotide coenzyme (DPN), adenosine triphosphate coenzyme (ATP), uridine diphosphate glucose coenzyme (UDPG), guanosine 5'-triphosphate coenzyme (GTP), glucose oxidase enzyme (GOD) and mixtures thereof; and (C) 0% to less than 50% of an enzyme selected from the group consisting of fructosediphosphate aldolase, phosphofructokinase, hexokinase, glucokinase, glucose 6-phosphate dehydrogenase, glucose phosphate isomerase, d-glucose-phosphotransferase and mixtures thereof, said com

Abstract: A method of degrading chloroethylene compounds is disclosed comprising incubating microorganisms capable of degrading chloroethylene compounds by an aromatic degradative pathway together with the chloroethylene compounds under conditions such that the aromatic degradative pathway is active.

Abstract: Lipid material or ganglioside from mammalian sources e.g. bovine and porcine brain or omentum is used to treat peptic ulcers.

Abstract: This invention relates to a method for preparation of a tissue graft composition from a segment of small intestine. A tissue graft composition is described which comprises the tunica submucosa of a segment of small intestine of a warm-blooded vertebrate wherein the tunica submucosa is deliminated from the tunica muscularis and at least the luminal portion of the tunica mucosa. The tissue graft composition has been shown to have excellent mechanical characteristics, as well as non-allergenicity and non-thrombogenicity in applications as vascular autografts, vascular allografts, and vascular heterografts.